OliX and Lilly Enter Global Licensing Agreement for MASH and …
2 days ago · OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016. ... 226950), a leading developer of …
Lilly inks AdvanCell, OliX deals to expand in radiopharma, MASH
1 day ago · Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on …
OliX and Lilly Enter Global Licensing Agreement for MASH and …
1 day ago · SEONGNAM, South Korea, February 10, 2025--OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016.
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
11 hours ago · Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its …
Eli Lilly enters global license agreement with OliX for OLX75016
2 days ago · OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly . This collaboration focuses on the development and commercialization of OliX’s OLX75016, a …
OliX strikes $630 million deal with Lilly for obesity and liver …
1 day ago · OliX Pharmaceuticals, a Korean biotech company specializing in RNA interference (RNAi) therapies, has signed an exclusive global licensing deal with Eli Lilly worth up to $630 …
OliX and Lilly Enter Global Licensing Agreement for MASH and …
1 day ago · OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company …
OliX Pharmaceuticals signs 910 billion won deal with Eli Lilly, hits ...
2 days ago · OliX Pharmaceuticals, a gene therapy developer, recorded a daily limit up on the 10th after news that it signed a global license agreement worth 910 billion won with Eli Lilly. …
Olix, Eli Lilly to develop liver disease drug under $630 million deal …
Olix will use the upfront payment to complete a phase 1 clinical trial for its candidate OLX702A in Australia while Eli Lilly will work on further research, development and commercialization.
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty …
1 day ago · Concurrently, Korea-based OliX Pharmaceuticals Inc. announced a global licensing agreement with Eli Lilly for the development and commercialization of OliX's OLX75016, a …
- Some results have been removed